Related references
Note: Only part of the references are listed.Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients
Miryam Yusufov et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy
Iris Noordhoek et al.
CLINICAL CANCER RESEARCH (2021)
Fragility fractures in Europe: burden, management and opportunities
Fredrik Borgstrom et al.
ARCHIVES OF OSTEOPOROSIS (2020)
Bone health in cancer: ESMO Clinical Practice Guidelines
R. Coleman et al.
ANNALS OF ONCOLOGY (2020)
Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: A Systemtic review and Meta-analysis
Fuxing Zhao et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Harold J. Burstein
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Management of Aromatase Inhibitor-Induced Musculoskeletal Symptoms
Arjun Gupta et al.
JCO ONCOLOGY PRACTICE (2020)
Fractures due to Aromatase Inhibitor Therapy for Breast Cancer: A Real-World Analysis of FAERS Data in the Past 15 Years
Yu Song et al.
ONCOLOGY RESEARCH AND TREATMENT (2020)
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi et al.
BRITISH JOURNAL OF CANCER (2019)
Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study
William D. Leslie et al.
ONCOLOGIST (2019)
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2019)
The cognitive effects of endocrine therapy in survivors of breast cancer: A prospective longitudinal study up to 6 years after treatment
Kathleen Van Dyk et al.
CANCER (2019)
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Thomas Ruhstaller et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours
Cigdem Selli et al.
BREAST CANCER RESEARCH (2019)
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis
Hadar Goldvaser et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis
Hadar Goldvaser et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al.
LANCET (2018)
Bone health during endocrine therapy for cancer
Tilman D. Rachner et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial
Lvana Sestak et al.
JAMA ONCOLOGY (2018)
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial
Ian Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial
Vivianne C. G. Tjan-Heijnen et al.
LANCET ONCOLOGY (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Optimal duration of adjuvant endocrine therapy: how to apply the newest data
Kerstin Wimmer et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)
Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer
Dara B. Bracken-Clarke et al.
BREAST CARE (2017)
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
P. E. Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Michael Gnant et al.
LANCET (2015)
Breast Cancer Statistics, 2013
Carol DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Breaking away: High fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients
Havard Soiland et al.
ACTA ONCOLOGICA (2013)
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27-A Randomized Controlled Phase III Trial
Paul E. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group
Peter C. Dubsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer
N. Lynn Henry et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial
Eleftherios P. Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
Raimund Jakesz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
PE Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
